Abstract

Glioblastoma multiforme (GBM) is clinically highly aggressive as a result of evolutionary dynamics induced by cross-talk between cancer cells and a heterogeneous group of immune cells in tumor microenvironment. The brain harbors limited numbers of immune cells with few lymphocytes and macrophages; thus, innate-like lymphocytes, such as γδ T cells, have important roles in antitumor immunity. Here, we characterized GBM-infiltrating γδ T cells, which may have roles in regulating the GBM tumor microenvironment and cancer cell gene expression. V(D)J repertoires of tumor-infiltrating and blood-circulating γδ T cells from four patients were analyzed by next-generation sequencing-based T-cell receptor (TCR) sequencing in addition to mutation and immune profiles in four GBM cases. In all tumor tissues, abundant innate and effector/memory lymphocytes were detected, accompanied by large numbers of tumor-associated macrophages and closely located tumor-infiltrating γδ T cells, which appear to have anti-tumor activity. The immune-related gene expression analysis using the TCGA database showed that the signature gene expression extent of γδ T cells were more associated with those of cytotoxic T and Th1 cells and M1 macrophages than those of Th2 cells and M2 macrophages. Although the most abundant γδ T cells were Vγ9Vδ2 T cells in both tumor tissues and blood, the repertoire of intratumoral Vγ9Vδ2 T cells was distinct from that of peripheral blood Vγ9Vδ2 T cells and was dominated by Vγ9Jγ2 sequences, not by canonical Vγ9JγP sequences that are mostly commonly found in blood γδ T cells. Collectively, unique GBM-specific TCR clonotypes were identified by comparing TCR repertoires of peripheral blood and intra-tumoral γδ T cells. These findings will be helpful for the elucidation of tumor-specific antigens and development of anticancer immunotherapies using tumor-infiltrating γδ T cells.

Highlights

  • Glioblastoma multiforme (GBM) progresses by co-opting stromal cells that reside in or are recruited to the tumor microenvironment (TME), which is a complex ecosystem composed of heterogeneous tumor cells associated with extensive hypoxic zones, reactive astrocytes, and infiltrating distinct immune components, including microglia, tumor-associated macrophages (TAMs) derived from peripheral blood monocytes, granulocytes, myeloid-derived suppressor cells (MDSCs), and T cells [1,2,3,4,5]

  • She received concurrent chemoradiotherapy with TMZ followed by adjuvant TMZ [47], and brain magnetic resonance imaging (MRI) during four adjuvant TMZ courses revealed tumor recurrence around the resection site

  • We investigated the γδ T-cell receptor (TCR) repertoires in tumor tissues and matched blood from four patients with IDH1 wild-type GBM

Read more

Summary

Introduction

Glioblastoma multiforme (GBM) progresses by co-opting stromal cells that reside in or are recruited to the tumor microenvironment (TME), which is a complex ecosystem composed of heterogeneous tumor cells associated with extensive hypoxic zones, reactive astrocytes, and infiltrating distinct immune components, including microglia, tumor-associated macrophages (TAMs) derived from peripheral blood monocytes, granulocytes, myeloid-derived suppressor cells (MDSCs), and T cells [1,2,3,4,5]. Vγ9Vδ2 T cells are activated by pyrophosphate-containing metabolites, generically known as phosphoantigens (pAgs), which are derived from microbes or metabolically active tumor cells and bind to the intracellular domain of the butyrophilinrelated molecule BTN3A1 without major histocompatibility complex (MHC)- or CD1-dependent antigen presentations [18, 21]. GBM cancer cells express several MHC-like stress-induced self-antigens (MIC-A/B), heat shock protein-60, U16-binding protein 4, human MutS homolog 2, and F1-ATP synthase, which are recognized by TCRs, Toll-like receptors, or natural killer (NK) receptors expressed on Vγ9Vδ2 T cells, triggering cancer cell killing without any prior antigen exposure or priming [15, 24,25,26].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call